Status:
TERMINATED
A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death
Lead Sponsor:
American University of Beirut Medical Center
Conditions:
Labor Induction
Eligibility:
FEMALE
16-45 years
Phase:
PHASE3
Brief Summary
Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer t...
Detailed Description
Prostaglandins have been recognized as effective abortifacients for several decades. Misoprostol, a synthetic analogue of prostaglandin E1, has several advantages over other prostaglandins that includ...
Eligibility Criteria
Inclusion
- 14 and 24 weeks of gestation
- Both nulliparous and multiparous women
- An unfavorable cervix (Bishop's score less than 8)
Exclusion
- Known contraindications to the use of prostaglandins (e.g. asthma)
- Previous uterine scar (previous cesarean or myomectomy where the endometrial cavity was entered)
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00141895
Start Date
September 1 2004
End Date
November 1 2008
Last Update
July 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
American University of Beirut Medical Center
Beirut, Lebanon